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Abstract: Endogeonus opioid peptides play
an important role in the generation of the
pre–ovulatory LH surge. We investigated the
interrelationship between the oploid and
indolaminergic systems in the regutalion of
LH secretion, and the involvement of µ–and
κ–opioid subtypes in this process. Concsious
female rats bearing cannula in the femoral
artery were injected intraperitoneally with
µ–(diamorphine) and κ–(U–50488H) opioid
agonists either alone or with their respective
antagonists, naloxone and MR2266, on
pro–oestrus. Blood samples were collected
hourly between 15.00 and 19.00 and plasma
LH levels were measured by RIA. 5–HT and
5–HIAA concentrations were determined by
HPLC–ECD in the MPOA, SCN, ME and ARN.
One–Way ANOVA was used to examine the
results.

the suppressive effects of diamorphine on LH
release, but MR2266 did not prevent the
effects of U–50488H. Concentrations of
5–HT and 5HIAA were selectively reduced by
the µ–and κ–agonists in the specific regions
of the hypothalamus. Naloxone and MR2266
negated the inhibitory effects of diamorphine
and U–50488H in an area–dependent
manner. Only diamorphine lowered the ratio
of 5–HIAA/5–HT in the MPOA, and these
effects were reversed in the same
hypothalamic
region
following
its
co–administration with naloxone.

Both µ– and κ– agonists inhibited the
pre–ovulatory LH surge. Naloxone prevented

Key Words: Indolamines, opioid receptors,
LH surge and HPLC–ECD.
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Introduction
Regualiton of gonadotrophin–releasing hormone
(GnRH) activity and hence luteinising hormone (LH)
release involves a multiplicity of brain neurotransmitter
systems including the monoamines and the opioids which
modulate GnRH neurones within the hypothalamus (1,
2). The opioid system exerts a physiological tonic
inhibitory effect on GnRH neurones as revealed by the
enhancement of LH release after treatment with the
opioid antagonist, naloxone (3, 4). Conversely,
administration of opioid agonists, just before the critical
period on the day of pro–oestrus, inhibits release of the
pre–ovulatory LH surge and hence ovulation (5, 6). Allen
and Kalra (7) have proposed that a reduction in the
endogenous opioid tone before the onset of the
pre–ovulatory LH surge may be the initial neural stimulus
for the generation of the LH surge. The existence of

The present results indicate that both µ– and
κ–opioid receptor subtypes may be involved
in the inhibition of the LH surge. The
physiological
significance
of
an
indolaminergic involvement in the opioid
control of LH release appears to be minor.

several different classes of opioid receptor subtypes has
been shown in the hypothalamus (8, 9).
Although direct synaptic connections exist between
opioid peptidergic nerve terminals and GnRH neurones in
the medial preoptic area (MPOA) and median eminence
(ME) (10) there is some evidence that the opioids can
affect GnRH release directly (11). There is also a bulk of
evidence indicating that the opioids act indirectly by
influencing the brain monoaminergic systems (12–14).
In the present study, we further investigated the
modulating effects of diamorphine (µ–agoinst) and
U–50488H (κ–agonist), either alone or when
co–administered with their receptor antagonists
(naloxone and MR2266, respectively) on the release of
LH and at the same time on the indolamine concentrations
in specific regions of the rat hypothalamus. The
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investigation was confined to the modulation of the
pre–ovulatory LH surge in conscious female rats on the
afternoon of pro–oestrus.
Materials and Methods
Adult female Sprague–Dawley rats (Harlan UK Ltd.,
Oxon, England) weighing 220–300 g were maintained
under controlled temperature (21±1 °C) and light
conditions (lights on from 07.00 to 19.00). Food and
water were provided ad libitum. Vaginal smearing was
performed each morning (09.00 to 10.00) and the
morphology of the cells present used to identify the
different stages of the oestrous cycle. Only those animals
which had exhibited at least three consecutive four–day
oestrous cycles were selected for experimentation.
On the late morning of pro–oestrus, a plastic cannula
(Portex, o.d. 0.63mm) combined with winly tubing (i.d.
0.55 mm) was inserted into the right femoral artery
under halothane anaesthesia (complete cessation of the
hind limb flexor withdrawal reflex). With the aid of a
stainless steel guide cannula, the vinyl tubing was fed
under the dorsal skin to emerge at the back of the neck.
The animals were allowed to recover and then in the early
afternoon, just before the onset of the pre–ovulatory LH
surge, intraperitoneally (IP) injected either with
diamorphine (3 mg/kg, n=10; Napp Laboratories Ltd,
Cambridge UK), U–50488H (10 mg/kg, n=8; Boehringer
Ingelheim, Germany), diamorphine plus naloxone (15
mg/kg, n=13; Sigma Chemicals Corporation, Poole,
Dorset, UK) or U–50488H plus MR2266 (10 mg/kg,
n=9; Boehringer Ingelheim, Germany). The controls
received saline alone (1 ml/kg; n=16). Blood samples
(200µl) were withdrawn through the heparinised cannula
at hourly intervals from the freely–moving conscious
animals throughout the afternoon of pro–oestrus,
commencing at 15.00. Drug administrations were carried
out under light halothane anaesthesia.
The blood samples collected were centrifuged at 4°C
for 10 mins at 3000 rpm. The plasma was then
transferred into fresh tubes and stored at –20°C until
assayed for LH determination by radioimmunassay (RIA).
At 1900 the animals were decapitated, and the brains
rapidly removed and frozen on dry ice. Five hundred
micrometer coronal brain slices were cut. The MPOA,
suprachiasmatic nucleus (SCN), ME and arcuate nucleus
(ARN) were micropunched using modified stainless steel
hypordemic needles (0.7 and 0.33mm internal diameter)
under a dissection microscope, according to the
stereotaxic atlas of the rat brain (15).
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Chromatography
The specific hypothalamic areas collected were kept at
–80°C prior to the analysis. One hundred microliters of
0.1M HCl was added to each sample, along with 50µl of
3,4–dihydroxybenzylamine: 1ng) as an internal standard.
The samples were homogenised and then centrifuged at
4°C for 10 mins at 3000 rpm. Ten microliter aliquots of
supernatant were injected onto a reverse phase high
performance liquid chromatographic (HPLC) column
(S5ODS2–250A, 5µm, 4.6mm i.d.x25cm, HICHROM)
coupled to an electrochemical detector (ECD, Model 141,
GILSON). The monoamine content of the hypothalamic
regions was simultaneously detected. The method has
been previously described (16).
LH Assay
Plasma LH levels were measured by RIA. The standard
used was NIADDK–rLH–RP–3 and the antibody
NIADDK–anti–rLH S10. RIA reagents were obtained from
the National Hormone and Pituitary Program (Baltimore,
Maryland, USA). The inter– and intra–assay coefficients
of variation were 8.0% and 9.5% respectively. The
sensitivity of the assay was 10 pg/tube (1ng/ml).
Protein Estimation
Protein estimations were made according to the
modified method of Lowry et al. (17). The method is
detailed in our previous report (16).
Statistics
The data were statistically analysed by using One–Way
Analysis of Variance (MINITAB for Windows, 10). The
level of significance was set at P<0.05.
Results

1. Effect of µ– and κ–agoinsts and antagonists on
hypothalamic indolamine concentrations:
The indolamine results are presented in Figure 1 and
Table 1. Although both diamorphine and U–50488H
altered 5–hydroxytryptamine (5–HT) concentrations in all
the hypothalamic regions examined, these changes were
not significantly different from those values seen in the
controls. MR2266 brought about significant increases in
5–HT levels in the SCN (P<0.05) and ARN (P<0.05), but
decreases in the MPOA (P<0.005), compared with those
which received U–50488H alone following its
co–administration with the κ–opioid agonist. The 5–HT
concentrations were also significantly elevated by
naloxone in only the SCN compared with the values seen
in the diamorpine–treated rats.
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SCN
18
a
12

b

9
6
3

5–HT levels (pg/µg protein)

15
12
9

c

6
3

0

ME

U–50+MR2266

U–50488H

5–HT
concentrations
(pg/µg protein±SEM) in the
MPOA, SCN, ME and ARN
of the rat hypothalamus at
19.00 on pro–oestrus
following administration or
co–administration of µ–
and κ–opioid agonists and
antagonists at 13.00 on the
same day. a: P<0.05
compared
with
the
diamorphine–treated
animals, b: P<0.05, c:
P<0.005 compared with
the
U–50488H–treated
animals, using One–Way
ANOVA.

ARN
15
5–HT levels (pg/µg protein)

15
12
9
6
3

12
c
9
6
3

U–50+MR2266

U–50488H

Saline

U–50+MR2266

U–50488H

Diamorp+NAL

Diamorphine

Saline

Diamorp+NAL

0

0

Diamorphine

5–HT levels (pg/µg protein)

Diamorp+NAL

Saline

U–50+MR2266

U–50488H

Diamorp+NAL

Diamorphine

Saline

0
Diamorphine

5–HT levels (pg/µg protein)

15

Table 1.

Figure 1.

MPOA

5–HIAA concentrations (pg amine/µg protein±SEM) in the MPOA, SCN, ME and ARN of the rat hypothalamus at 19.00 on pro–oestrus
after administration or co–administraiton of µ– and κ–opioid agonists and antagonists at 13.00 on the same day. a: P<0.05 compared
with the saline–, b: P<0.01 compared with the diamorphine–, c: P<0.05 compared with the U–50488H–treated animals. ANOVA was
used to examine the data.

Area

Saline
(n=16)

Diamorphine
(n=10)

Diamor+NAL
(n=13)

U–50488H
(n=8)

U–50+MR2266
(n=9)

MPOA
SCN
ME
ARN

7.2±0.9
7.3±1.3
7.8±1.1
6.7±1.1

4.0±0.9 a
6.1±1.6
4.5±1.1 a
6.0±1.5

10.0±1.6 b
11.1±2.4
14.5±3.0 b
13.8±5.0

5.5±1.1
5.7±1.0
4.1±0.6 a
4.1±0.9

5.7±1.4
7.5±1.3
5.6±1.2
7.4±1.2 c
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(12)

35
30
25
(5)
**

20
15
10

(10)
*

5

2. Effect of µ– and κ–agonists and antagonists on LH
release on the afternoon of pro–oestrus:
Plasma samples were obtained at hourly intervals
between 15.00 and 19.00 on the afternoon of
pro–oestrus and the LH concentrations were seen to rise
significantly to a peak at 18.00 hours with a slight
nonsignificant fall at 19.00 hours (LH levels ng/ml±SEM:
at 15.00 hours = 3.1±1.3; 16.00 hours = 11.5±4.1;
17.00 hours = 22.3±7.9; 18.00 hours = 27.3±9.4;
19.00 hours = 23.6±6.3). These LH results are
consistent with those reported by Dow et al. (18) using
the same experimental technique. Administration of
U–50488H at 13.00 completely suppressed plasma LH
levels throughout the afternoon of pro–oestrus. The
κ–antagonist, MR2266, failed to prevent the inhibitory
effects of the κ–agonist on LH secretion in 8/9 rats with
one animal showing a rise to peak LH levels of 19.5 ng/ml

Table 2.

Area

MPOA
SCN
ME
ARN
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Figure 2.

Diamorp+NAL

Diamorphine

0
Saline

The ratio of 5–HIAA/5–HT (Table 2) was significantly
lowered by diamorphine in only the MPOA compared with
that seen in the controls (P<0.01). These suppressive
effects were negated in the same hypothalamic area when
the µ–agonist was co–injected with naloxone (P<0.01).
Neither U–50488H nor its co–administration with the
κ–opioid antagonist significantly altered the ratio of
5–HIAA/5–HT in any of the hypothalamic regions
examined.

40

Plasma LH levels (ng/ml)

Concentrations
of
the
5–HT
metabolite
(5–hydroxyindole acetic acid; 5–HIAA) were significantly
decreased by the µ–agonist in the MPOA (P<0.05) and
ME (P<0.05). These inhibitory effects were prevented in
the same hypothalamic areas following the
co–administration of diamorphine with naloxone
(P<0.01). The κ–agonist reduced 5–HIAA levels in only
the ME (P<0.05), and its combination with MR2266
resulted in significant increases in the ARN compared with
those which received U–50488H alone (P<0.05).

Peak concentrations of LH over the afternoon of
pro–oestrus in conscious rats treated with saline,
diamorphine alone or with naloxone. Numbers in each
group are given in brackets. * P<0.01 compared with
saline–treated animals; ** P<0.05 compared with the
diamorphine–treated animals using One–Way ANOVA.

at 19.00 hours. Administration of diamorphine
suppressed plasma LH levels in 5/10 rats with five
animals showing a rise to peak concentrations of 18.5,
12.8, 10.9, 10.7 and 5.5 ng/ml each at 18.00 hours and
19.00 hours sampling intervals. This inhibitory effect of
diamorphine was reversed in 5/6 rats which were given
15 mg/kg naloxone concomitantly with the µ–agonist.
Peak concentrations of LH over the afternoon of
pro–oestrus are shown in Figure 2.

Ratio of 5–HT/5–HIAA (Mean±SEM) in the MPOA, SCN, ME and ARN of the rat hypothalamus at 19.00 on pro–oestrus after administration
or co–administration of µ– and κ–opioid agonists and antagonists at 13.00 on the same day. a: P<0.01 compared with the saline–, b:
P<0.01 compared with the diamorphine–treated animals. ANOVA was used to examine the data.

Saline
(n=16)

Diamorphine
(n=10)

Diamor+NAL
(n=13)

U–50488H
(n=8)

U–50+MR2266
(n=9)

0.962±0.140
1.311±0.300
1.172±0.234
6.7±1.1

0.430±0.106 a
1.365±0.440
1.153±0.281
6.0±1.5

1.048±0.165 b
0.968±0.156
1.078±0.112
13.8±5.0

0.796±0.324
0.997±0.213
0.624±0.144
4.1±0.9

0.783±0.169
0.736±0.116
0.643±0.149
7.4±1.2 c
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Discussion
The hypothalamus is densely populated by opioid
receptors while the anterior pituitary contains only a very
low density of these (19). The opioids have been shown
to have no direct action on LH release from the anterior
pituitary (20). It is therefore suggested that the µ– and
κ–opioid agonists in this study exerted their inhibitory
effects at the hypothalamic level. This is in line with the
evidence that administration of morphine suppresses the
release of GnRH (11) and naloxone infusion increases its
secretion from the medial basal–preoptic area in vitro
(21).
The ability of morphine (a µ–agonist) to suppress LH
secretion has been demonstrated in a variety of
experimental conditions (see 6). The results of the
present study support this hypothesis, as the µ–opioid
receptor agonist, diamorphine, also reduced the secretion
of LH on the afternoon of pro–oestrus. When
diamorphine was co–administered with naloxone, the
opioid inhibition of the LH release was prevented. This
suggests that increased LH release results from an
antagonism at post–synaptic µ–opioid receptors. Also, the
inhibitory opioidergic tone, although decreased, is not
totally eliminated during the critical period.
There are conflicting reports on the involvement of
κ–opioid receptors in the regulation of LH secretion.
Inhibition of LH release occurs after administration of
specific κ–opioid agonists (22, 23). However, the
specificity of the κ–opioid effect has been questioned
(24). In the present study, the LH surge was completely
abolished by a selective κ–agonist throughout the
afternoon of pro–oestrus. The κ–opioid action on LH
release is believed to be mediated at the level of the
hypothalamus in view of the finding that κ–agonists
inhibit GnRH release in vitro (25). The κ–receptor
antagonist, MR2266, failed to reverse the suppressive
effects of U–50488H on plasma LH levels. It has been
reported that MR2266 has also µ–agonist properties
(26). Although the present results imply participation of
κ–opioid receptors in the LH secretory systems, further
studies using more selective antagonists may reveal
additional information.
The studies on the involvement of the serotonergic
system upon LH release have been controversial; both a
stimulatory and an inhibitory role of 5–HT on LH
secretion have been reported (27–29). 5–HT may
mediate, at least in part, the effects of endogenous opioid
peptides on the LH secretory systems. Morphine

stimulates LH release in the presence of exogenous 5–HT,
but is inhibitory in its absence (30). Synaptic contacts
between the serotonergic terminals and immunoreactive
GnRH perikarya have been visualised in the rat
hypothalamus (31). The µ–opioid agonist, diamorphine,
reduced the LH surge in association but had no effect on
5–HT levels in any of the four hypothalamic areas
examined. However, it selectively decreased the
concentrations of 5–HIAA in the MPOA and ME in a
naloxone–reversible fashion. Moreover, the ratio of
5–HIAA/5–HT was also lowered in the MPOA, and the
effect was negated by naloxone in this area. It has
previously been suggested that naloxone enhancement of
the pre–ovulatory LH surge is primarily mediated by
5–HT in the MPOA (4). These results would point to a
modulatory action of the µ–opioid subtype on the 5–HT
metabolism (or turnover) in the MPOA and ME rather
than its release from the nerve terminals. However, it was
expected that the opioids would reduce not only the
metabolism of this indoleamine but also its release as
well.
Although U–50488H was very successful in blocking
the LH surge, it did not significantly alter the
concentrations of 5–HT or its metabolite in any of the
hypothalamic areas examined except that 5–HIAA levels
were lowered in the ME. Interestingly, 5–HT levels were
elevated in the SCN and ARN, but reduced in the MPOA
following the co–administration of U–50488H with
MR2266. This κ–opioid antagonist also increased
concentrations of 5–HIAA in only the ARN in comparison
with those rats receiving U–50488H alone. Activation of
κ–opioid receptors has been shown to pre–synaptically
inhibit 5–HT release in the dorsal raphe nucleus (32). The
results of the present study were not consistent and
difficult to interpret. Previous attempts to reveal the
putative nature of interaction between κ–opioid receptors
and serotonergic neurotransmission have also been
inconclusive (23).
In conclusion, activation of the µ– and κ–opioid
receptors may exert an inhibitory influence on LH release,
since both diamorphine and U–50488H inhibited the
pre–ovulatory LH surge. Although pharmacological
studies have suggested a role for the serotonergic system
in the central regulation of LH surge, the physiological
significance of its involvement in this process appears to
be minor. The present results suggest that µ– and
κ–opioid agonists (diamorphine and U–50488H) may
have inhibitory effects on 5–HT release and/or turnover
in discrete hypothalamic areas.
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